Home/Filings/4/0000899243-21-005666
4//SEC Filing

Moxham Christopher 4

Accession 0000899243-21-005666

CIK 0001680581other

Filed

Feb 9, 7:00 PM ET

Accepted

Feb 10, 4:30 PM ET

Size

5.4 KB

Accession

0000899243-21-005666

Insider Transaction Report

Form 4
Period: 2021-02-08
Moxham Christopher
Chief Scientific Officer
Transactions
  • Award

    Stock Option (right to buy)

    2021-02-08+100,000100,000 total
    Exercise: $12.60Exp: 2031-02-07Common Stock (100,000 underlying)
Footnotes (1)
  • [F1]This option was granted on February 8, 2021 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of February 6, 2021, subject to continued service.

Issuer

Fulcrum Therapeutics, Inc.

CIK 0001680581

Entity typeother

Related Parties

1
  • filerCIK 0001843784

Filing Metadata

Form type
4
Filed
Feb 9, 7:00 PM ET
Accepted
Feb 10, 4:30 PM ET
Size
5.4 KB